Multiple Sclerosis Clinical Trials in Philadelphia

Showing 141-160 of 634 trials

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

NCT02400190

This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.

Breast Neoplasms

University of Michigan Rogel Cancer Center202 participantsStarted May 2015

Stanford, California, United States • New Haven, Connecticut, United States • Maywood, Illinois, United States +10 more locations

RECRUITING< 1 mile

Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2

NCT01193088

This project includes two projects. One is looking for new genes that cause Charcot Marie Tooth disease (CMT). The other is looking for genes that do not cause CMT, but may modify the symptoms a person has.

Charcot-Marie-Tooth Disease, Type Ia (Disorder)HMSN

University of Iowa1,050 participantsStarted May 2010

Los Angeles, California, United States • Palo Alto, California, United States • Aurora, Colorado, United States +19 more locations

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2

Multiple Sclerosis Trials in Other Cities

Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis

A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Integrated Model for Promoting Parenting and Early School Readiness in Pediatrics

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Biobank For MS And Other Demyelinating Diseases

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

Study of Diagnostic Performance of [18F]CTT1057 in BCR

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

Other Conditions in Philadelphia